Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial
Why the study?
Does ivabradine improve exercise duration in patients with chronic stable angina receiving beta-blocker therapy?
Population
889 patients with chronic stable angina pectoris receiving atenolol 50 mg/day
Comparison
Ivabradine 5 mg b.i.d. for 2 months, increased… vs Placebo
Design
RCT, randomized, double-blinded
Follow-up
4 months
Authors
Discussion
Loading...
Member takes
Implication
Supports adjunctive ivabradine for improved exercise capacity in beta-blocker-treated stable angina; reinforces heart-rate reduction benefits in this RCT.
Structured PICO
Does ivabradine improve exercise duration in patients with chronic stable angina receiving beta-blocker therapy?
P
Population
889 patients with chronic stable angina pectoris receiving atenolol 50 mg/day
I
Intervention
Ivabradine 5 mg b.i.d. for 2 months, increased to 7.5 mg b.i.d. for a further 2 months
C
Comparator
Placebo
O
Outcome
Total exercise duration at 4 months measured by treadmill exercise tests at the trough of drug activity using the standard Bruce protocolsurrogate
Adding ivabradine to standard beta-blocker therapy significantly improves exercise capacity in patients with chronic stable angina.
Cite This Study
Tardif et al. (2009) studied this question.